RESOLUTION NO. R18-75

A RESOLUTION AUTHORIZING THE MAYOR TO SIGN AN **AGREEMENT BETWEEN THE CITY OF LAUREL AND** THE DRUG ENFORCEMENT ADMINISTRATION "DEA" ASSIGNING A LAUREL POLICE OFFICER TO THE TACTICAL DIVISION SQUAD TASK FORCE FOR A **ONE-YEAR PERIOD.**

WHEREAS, the DEA formed the Tactical Division Squad Task Force to investigate trafficking of controlled substance pharmaceuticals in the greater Montana area; and

WHEREAS, the City of Laurel is aware of the abuse of controlled pharmaceuticals and the trafficking thereof in and surrounding the City of Laurel, and that these illegal activities are detrimental to the welfare of the City and its citizens; and

WHEREAS, the City finds it reasonable and necessary to assign a Laurel Police Officer to assist the DEA Task Force in meeting its objectives.

NOW, THEREFORE, BE IT RESOLVED by the City Council of the City of Laurel, Montana, that the Mayor is authorized to sign the Tactical Diversion Squad Task Force Agreement between the City of Laurel and the Drug Enforcement Administration, a copy of which is attached hereto.

INTRODUCED at a regular meeting of the City Council on October 16, 2018 by Council Member Mountsier.

PASSED and APPROVED by the City Council of the City of Laurel this 16th day of October, 2018.

APPROVED by the Mayor this 16th day of October, 2018.

CITY OF LAUREL

Thomas C. Nelson, Mayor

Clerk-Treasurer

Approved as to Form:

Sam Painter, Civil City Attorney

R18-75 DEA Task Force – LPD Agreement



U. S. Department of Justice Drug Enforcement Administration

Denver Field Division Office of the Special Agent in Charge 12154 East Easter Avenue Centennial, Colorado 80112

www.dea.gov

Chief Rick Musson Laurel Police Department 214 West 1st Street Laurel, Montana 59044

SEP 0 7 2018

Dear Chief Musson:

Enclosed please find the Task Force Agreement for the investigator you have assigned to the Denver Field Division as well as the OJP Form 4061/6. It is anticipated this position will be encumbered by:

William F. Brew III – Tactical Diversion Squad - Billings (DCFA Funded)

If you concur with this Task Force Agreement, please sign and return it along with the OJP Form 4061/6 to my office by September 30, 2018. DEA requires signatures on these agreements before payment can be made. Upon my signature, copies will be returned to your office for your files.

DEA invoices for reimbursement can be emailed to invoice.denver@usdoj.gov or mailed to:

Drug Enforcement Administration Attn: Fiscal Department 12154 East Easter Avenue Centennial, Colorado 80112

Submitted invoices must include an invoice number; invoice date; and officer's name, overtime rate, and daily overtime hours paid. Invoices claiming an indirect personnel cost will not be paid and will be returned to your agency. Please be advised your System Award Management (SAM) must be current in order for invoices to be processed for payment.

Should you have any questions or comments, please have your staff Program Support Specialist Shanda Meis at 720-895-4123 or via email at <u>Shanda.L.Meis@usdoj.gov</u>.

Sincerely,

William T. McDermott Special Agent in Charge

Enclosures: Task Force Agreement – DCFA Funded OJP Form 4061/6

TACTICAL DIVERSION TASK FORCE AGREEMENT

This agreement is made this <u>1st</u> day of <u>October</u>, 20<u>18</u>, between the United States Department of Justice, Drug Enforcement Administration (hereinafter "DEA"), and the <u>Laurel Police</u> <u>Department</u> (hereinafter "<u>LPD</u>"). The DEA is authorized to enter into this cooperative agreement concerning the use and abuse of controlled substances under the provisions of 21 U.S.C. § 873.

WHEREAS there is evidence that trafficking in controlled substance pharmaceuticals and/or listed chemicals exists in the <u>Montana</u> area and that such illegal activity has a substantial and detrimental effect on the health and general welfare of the people of <u>Montana</u>, the parties hereto agree to the following:

- 1. The <u>Tactical Diversion Squad Billings</u> Task Force will perform the activities and duties described below:
 - a. Investigate, disrupt, and dismantle individuals and/or organizations involved in diversion schemes (e.g., "doctor shopping", prescription forgery, and prevalent retail-level violators) of controlled pharmaceuticals and/or listed chemicals in the <u>Montana</u> area;
 - b. Investigate, gather, and report intelligence data relating to trafficking of controlled pharmaceuticals and/or listed chemicals; and
 - c. Conduct undercover operations where appropriate and engage in other traditional methods of investigation in order that the Task Force's activities will result in effective prosecution before the courts of the United States and the State of <u>Montana</u>.
- To accomplish the objectives of the <u>Tactical Diversion Squad Billings</u> Task Force, the <u>LPD</u> agrees to detail <u>one</u> (1) experienced officer(s) to the <u>Tactical Diversion Squad -</u> <u>Billings</u> Task Force for a period of not less than two years. During this period of assignment, the <u>LPD</u> officer(s) will be under the direct supervision and control of a DEA Supervisory Special Agent assigned to the Task Force.
- The <u>LPD</u> officer(s) assigned to the Task Force shall adhere to DEA policies and procedures. Failure to adhere to DEA policies and procedures shall be grounds for dismissal from the Task Force.
- 4. The <u>LPD</u> officers assigned to the Task Force shall be deputized as Task Force Officer(s) of DEA pursuant to 21 U.S.C. Section 878.
- 5. To accomplish the objectives of the <u>Tactical Diversion Squad Billings</u> Task Force, DEA will assign <u>three (3)</u> Special Agents and <u>two (2)</u> Diversion Investigators to the Task Force. DEA will also, subject to the availability of annual Diversion Control Fee Account (DCFA) funds or any continuing resolution thereof, provide necessary funds, vehicles, and equipment to support the activities of the DEA Special Agents and <u>LPD</u>

officer(s) assigned to the Task Force. This support will include: vehicles, office space, office supplies, travel funds, funds for the purchase of evidence and information, investigative equipment, training, and other support items, as available DCFA funds permit. Task Force Officers must record their work hours via DEA's activity reporting system.

- 6. During the period of assignment to the <u>Tactical Diversion Squad Billings</u> Task Force, the <u>LPD</u> will be responsible for establishing the salary and benefits, including overtime, of the officer(s) assigned to the Task Force and for making all payments due them. DEA will, subject to availability of funds, reimburse the agency/department for overtime payments made by it to <u>LPD</u> officer(s) assigned to the <u>Tactical Diversion Squad -</u> <u>Billings</u> Task Force for overtime, up to a sum equivalent to 25 percent of the salary of a GS-12, Step 1, (RUS) Federal employee (currently <u>\$18,343.75</u>), per officer. Note: Task Force Officer's overtime "Shall not include any costs for benefits, such as retirement, FICA, and other expenses."
- 7. In no event will the <u>LPD</u> charge any indirect cost rate to DEA for the administration or implementation of this agreement.
- 8. The <u>LPD</u> shall maintain on a current basis complete and accurate records and accounts of all obligations and expenditures of funds under this agreement in accordance with generally accepted accounting principles and instructions provided by DEA to facilitate on-site inspection and auditing of such records and accounts.
- 9. The <u>LPD</u> shall permit and have readily available for examination and auditing by DEA, the United States Department of Justice, the Comptroller General of the United States, and any of their duly authorized agents and representatives, any and all records, documents, accounts, invoices, receipts, or expenditures relating to this agreement. The <u>LPD</u> shall maintain all such reports and records until all litigation, claim, audits, and examinations are completed and resolved, or for a period of three (3) years after termination of this agreement, whichever is later.
- 10. The <u>LPD</u> shall comply with Title VI of the Civil Rights Act of 1964, Section 504 of the Rehabilitation Act of 1973, the Age Discrimination Act of 1975, as amended, and all requirements imposed by or pursuant to the regulations of the United States Department of Justice implementing those laws, 28 C.F.R. Part 42, Subparts C, F, G, H and I.
- 11. The <u>LPD</u> agrees that an authorized officer or employee will execute and return to DEA the attached OJP Form 4061/6, Certification Regarding Lobbying; Debarment, Suspension and Other Responsibility Matters; and Drug-Free Workplace Requirements. The <u>LPD</u> acknowledges that this agreement will not take effect and no Federal funds will be awarded to the <u>LPD</u> by DEA until the completed certification is received.
- 12. When issuing statements, press releases, requests for proposals, bid solicitations, and other documents describing projects or programs funded in whole or in part with Federal money, the <u>LPD</u> shall clearly state: (1) the percentage of the total cost of the program or

project which will be financed with Federal money and (2) the dollar amount of Federal funds for the project or program.

The term of this agreement shall be effective from the date in paragraph number one until 13. September 30, 2019. This agreement may be terminated by either party on thirty days' advance written notice. Billing for all outstanding obligations must be received by DEA within 90 days of the date of termination of this agreement. DEA will be responsible only for obligations incurred by LPD during the term of this agreement.

For the Drug Enforcement Administration:

Date: 10/29/18

William T. McDermott Special Agent in Charge

For the Laurel Police Department:

Rick Musson

Chief

Date: 10-22-18

THOMAS C NELSON

MAYOR

16/22/2018

1



U.S. DEPARTMENT OF JUSTICE OFFICE OF JUSTICE PROGRAMS OFFICE OF THE COMPTROLLER

CERTIFICATIONS REGARDING LOBBYING; DEBARMENT, SUSPENSION AND OTHER RESPONSIBILITY MATTERS; AND DRUG-FREE WORKPLACE REQUIREMENTS

Applicants should refer to the regulations cited below to determine the certification to which they are required to attest. Applicants should also review the instructions for certification included in the regulations before completing this form. Signature of this form provides for compliance with certification requirements under 28 CFR Part 69, "New Restrictions on Lobbying" and 28 CFR Part 67, "Government-wide Debarment and Suspension (Nonpro-curement) and Government-wide Requirements for Drug-Free Workplace (Grants)." The certifications shall be treated as a material representation of fact upon which reliance will be placed when the Department of Justice determines to award the covered transaction, grant, or cooperative agreement.

1. LOBBYING

As required by Section 1352, Title 31 of the U.S. Code, and implemented at 28 CFR Part 69, for persons entering into a grant or cooperative agreement over \$100,000, as defined at 28 CFR Part 69, the applicant certifies that:

(a) No Federal appropriated funds have been paid or will be paid, by or on behalf of the undersigned, to any person for influencing or attempting to influence an officer or employee of any agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress in connection with the making of any Federal grant, the entering into of any cooperative agreement, and the extension, continuation, renewal, amendment, or modification of any Federal grant or cooperative agreement;

(b) If any funds other than Federal appropriated funds have been paid or will be paid to any person for influencing or attempting to influence an officer or employee of any agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress in connection with this Federal grant or cooperative agreement, the undersigned shall complete and submit Standard Form - LLL, "Disclosure of Lobbying Activities," in accordance with its instructions;

(c) The undersigned shall require that the language of this certification be included in the award documents for all subawards at all tiers (including subgrants, contracts under grants and cooperative agreements, and subcontracts) and that all subrecipients shall certify and disclose accordingly.

2. DEBARMENT, SUSPENSION, AND OTHER RESPONSIBILITY MATTERS (DIRECT RECIPIENT)

As required by Executive Order 12549, Debarment and Suspension, and implemented at 28 CFR Part 67, for prospective participants in primary covered transactions, as defined at 28 CFR Part 67, Section 67.510---

A. The applicant certifies that it and its principals:

(a) Are not presently debarred, suspended, proposed for debarment, declared ineligible, sentenced to a denial of Federal benefits by a State or Federal court, or voluntarily excluded from covered transactions by any Federal department or agency;

(b) Have not within a three-year period preceding this application been convicted of or had a civil judgment rendered against them for commission of fraud or a criminal offense in connection with obtaining, attempting to obtain, or performing a public (Federal, State, or local) transaction or contract under a public transaction; violation of Federal or State antitrust statutes or commission of embezzlement, theft, forgery, bribery, falsification or destruction of records, making false statements, or receiving stolen property;

(c) Are not presently indicted for or otherwise criminally or civilly charged by a governmental entity (Federal, State, or local) with commission of any of the offenses enumerated in paragraph (1)(b) of this certification; and

(d) Have not within a three-year period preceding this application had one or more public transactions (Federal, State, or local) terminated for cause or default; and

B. Where the applicant is unable to certify to any of the statements in this certification, he or she shall attach an explanation to this application.

3. DRUG-FREE WORKPLACE (GRANTEES OTHER THAN INDIVIDUALS)

As required by the Drug-Free Workplace Act of 1988, and implemented at 28 CFR Part 67, Subpart F, for grantees, as defined at 28 CFR Part 67 Sections 67.615 and 67.620—

A. The applicant certifies that it will or will continue to provide a drug-free workplace by:

(a) Publishing a statement notifying employees that the unlawful manufacture, distribution, dispensing, possession, or use of a controlled substance is prohibited in the grantee's workplace and specifying the actions that will be taken against employees for violation of such prohibition;

(b) Establishing an on-going drug-free awareness program to inform employees about-

(1) The dangers of drug abuse in the workplace;

(2) The grantee's policy of maintaining a drug-free workplace;

(3) Any available drug counseling, rehabilitation, and employee assistance programs; and

(4) The penalties that may be imposed upon employees for drug abuse violations occurring in the workplace;

(c) Making it a requirement that each employee to be engaged in the performance of the grant be given a copy of the statement required by paragraph (a);

(d) Notifying the employee in the statement required by paragraph (a) that, as a condition of employment under the grant, the employee will(1) Abide by the terms of the statement; and

(2) Notify the employer in writing of his or her conviction for a violation of a criminal drug statute occurring in the workplace no later than five calendar days after such conviction;

(e) Notifying the agency, in writing, within 10 calendar days after receiving notice under subparagraph (d)(2) from an employee or otherwise receiving actual notice of such convic-tion. Employers of convicted employees must provide notice, including position title, to: Department of Justice, Office of Justice Programs, ATTN: Control Desk, 633 Indiana Avenue, N.W., Washington, D.C. 20531. Notice shall include the identification number(s) of each affected grant;

(f) Taking one of the following actions, within 30 calendar days of receiving notice under subparagraph (d)(2), with respect to any employee who is so convicted—

(1) Taking appropriate personnel action against such an employee, up to and including termination, consistent with the requirements of the Rehabilitation Act of 1973, as amended; or

(2) Requiring such employee to participate satisfactorily in a drug abuse assistance or rehabilitation program approved for such purposes by a Federal, State, or local health, law enforcement, or other appropriate agency;

(g) Making a good faith effort to continue to maintain a drugfree workplace through implementation of paragraphs (a), (b), (c), (d), (e), and (f).

B. The grantee may insert in the space provided below the site(s) for the performance of work done in connection with the specific grant:

Place of Performance (Street address, city, county, state, zip code)

Check $\hfill\square$ if there are workplaces on file that are not indentified here.

Section 67, 630 of the regulations provides that a grantee that is a State may elect to make one certification in each Federal fiscal year. A copy of which should be included with each application for Department of Justice funding. States and State agencies may elect to use OJP Form 4061/7.

Check if the State has elected to complete OJP Form 4061/7.

DRUG-FREE WORKPLACE . (GRANTEES WHO ARE INDIVIDUALS)

As required by the Drug-Free Workplace Act of 1988, and implemented at 28 CFR Part 67, Subpart F, for grantees, as defined at 28 CFR Part 67; Sections 67.615 and 67.620-

A. As a condition of the grant, I certify that I will not engage in the unlawful manufacture, distribution, dispensing, possession, or use of a controlled substance in conducting any activity with the grant; and

B. If convicted of a criminal drug offense resulting from a violation occurring during the conduct of any grant activity, I will report the conviction, in writing, within 10 calendar days of the conviction, to: Department of Justice, Office of Justice Programs, ATTN: Control Desk, 810 Seventh Street NW., Washington, DC 20531.

As the duly authorized representative of the applicant, I hereby certify that the applicant will comply with the above certifications.

1. Grantee Name and Address:

2. Application Number and/or Project Name

3. Grantee IRS/Vendor Number

4. Typed Name and Title of Authorized Representative

5. Signature

10/18/2018